High-level Skp2 expression in pancreatic ductal adenocarcinoma: Correlation with the extent of lymph node metastasis, higher histological grade, and poorer patient outcome

被引:36
作者
Einama, Takahiro
Kagata, Yutaka
Tsuda, Hitoshi
Morita, Daisaku
Ogata, Sho
Ueda, Shigeto
Takigawa, Toshimichi
Kawarabayashi, Nobuaki
Fukatsu, Kazuhiko
Sugiura, Yoshiaki
Matsubara, Osamu
Hatsuse, Kazuo
机构
[1] Natl Def Med Coll, Dept Pathol 2, Tokorozawa, Saitama 3598513, Japan
[2] Natl Def Med Coll, Dept Surg 1, Tokorozawa, Saitama 3598513, Japan
[3] Natl Def Med Coll, Lab Med & Surg 2, Tokorozawa, Saitama 3598513, Japan
关键词
Skp2; pancreatic adenocarcinoma; prognosis; inummohistochemistry;
D O I
10.1097/01.mpa.0000220862.78248.c4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives: Recent studies have shown that overexpression of S-phase kinase-associated protein 2 (Skp2) occurs in many cancers at an advanced stage. We examined the clinicopathologic significance and prognostic implication of Skp2 expression in pancreatic invasive ductal carcinoma. Methods: Tissue samples from 46 pancreatic carcinomas were examined immunohistochemically for Skp2. The proportion of constituent tumor cells with Skp2 expression was analyzed and classified as high-level nuclear expression when more than 20% of the cancer cells were positive, or low-level nuclear expression otherwise. Results: High-level Skp2 overexpression was detected in 13 (28.3%) of the 46 tumors. The incidence of high-level Skp2 was correlated with higher histological grade (P = 0.0056), the extent of lymph node metastasis (P = 0.0086), the level of lymphatic permeation (P = 0.0024), and poorer patient outcome (P = 0.0189). Multivariate analysis showed that high-level Skp2 expression was an independent predictor of overall patient survival (P = 0.0140). Conclusions: It is suggested that examination of Skp2 expression might be clinically useful for prognostication in patients with pancreatic carcinoma and that Skp2 protein might be a novel therapeutic molecular target.
引用
收藏
页码:376 / 381
页数:6
相关论文
共 36 条
  • [1] SKP2 associates with p130 and accelerates p130 ubiquitylation and degradation in human cells
    Bhattacharya, S
    Garriga, J
    Calbó, J
    Yong, T
    Haines, DS
    Graña, X
    [J]. ONCOGENE, 2003, 22 (16) : 2443 - 2451
  • [2] TREATMENT AND SURVIVAL IN 13560 PATIENTS WITH PANCREATIC-CANCER, AND INCIDENCE OF THE DISEASE, IN THE WEST MIDLANDS - AN EPIDEMIOLOGIC-STUDY
    BRAMHALL, SR
    ALLUM, WH
    JONES, AG
    ALLWOOD, A
    CUMMINS, C
    NEOPTOLEMOS, JP
    [J]. BRITISH JOURNAL OF SURGERY, 1995, 82 (01) : 111 - 115
  • [3] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
    Burris, HA
    Moore, MJ
    Andersen, J
    Green, MR
    Rothenberg, ML
    Madiano, MR
    Cripps, MC
    Portenoy, RK
    Storniolo, AM
    Tarassoff, P
    Nelson, R
    Dorr, FA
    Stephens, CD
    VanHoff, DD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) : 2403 - 2413
  • [4] SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27
    Carrano, AC
    Eytan, E
    Hershko, A
    Pagano, M
    [J]. NATURE CELL BIOLOGY, 1999, 1 (04) : 193 - 199
  • [5] Overexpression of Skp2 in carcinoma of the cervix does not correlate inversely with p27 expression
    Dowen, SE
    Scott, A
    Mukherjee, G
    Stanley, MA
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2003, 105 (03) : 326 - 330
  • [6] Amplification of chromosome 5p correlates with increased expression of Skp2 in HPV-immortalized keratinocytes
    Dowen, SE
    Neutze, DM
    Pett, MR
    Cottage, A
    Stern, P
    Coleman, N
    Stanley, MA
    [J]. ONCOGENE, 2003, 22 (16) : 2531 - 2540
  • [7] Skp2 is oncogenic and overexpressed in human cancers
    Gstaiger, M
    Jordan, R
    Lim, M
    Catzavelos, C
    Mestan, J
    Slingerland, J
    Krek, W
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (09) : 5043 - 5048
  • [8] Harada T, 2002, CANCER RES, V62, P835
  • [9] Hershko D, 2001, CANCER, V91, P1745, DOI 10.1002/1097-0142(20010501)91:9<1745::AID-CNCR1193>3.0.CO
  • [10] 2-H